mechanism of glp 1 receptor agonist Frontiers PDB-101: Molecule of the Month:
Description
At full therapeutic doses, roughly 40% of patients experience GI side effects severe enough to consider stopping
Gromada J, Holst JJ, and Rorsman P
How Long Will Results Last
[DOI] [PubMed] [Google Scholar] 86.Clifton P
